Abstract 3659: WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3659
Abstract: Patients diagnosed with acute myeloid leukemia (AML) may not be eligible for curative intensive treatment due to co-morbidity factors or age. Here we report results of 5 AML patients in morphological remission after incomplete induction/consolidation… read more here.
Keywords: aml patients; prame; specific immune; immune responses ... See more keywords
Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142691
Abstract: Introduction: The addition of gemtuzumab ozogamicin (GO) to 7+3 chemotherapy for newly diagnosed acute myeloid leukemia (AML) has been shown to significantly improve event-free survival (EFS) for cytogenetically favorable-risk AML, with marginal benefit for intermediate-risk… read more here.
Keywords: risk; adverse risk; membership entity; risk pts ... See more keywords
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003159
Abstract: CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and… read more here.
Keywords: high risk; real life; cpx 351; aml ... See more keywords